

1 **Figure S1.** CCDC6 expression in HCC based on TP53 mutation status and the DFI curves in
2 HCC/CCA based on CCDC6 expression level (A)The correlation between CCDC6 and TP53
3 mutation of HCC according to UALCAN database. (B-C) the DFI curves in HCC/CCA based on
4 CCDC6 expression level according to TCGA database.

5

6 **Figure S2.** Representative IHC-stained slides of HCC/iCCA from the Human Protein Atlas (HPA).
7 (A-B) Representative IHC-stained slides of HCC. (C). Representative IHC-stained slides of HCC.
8 (D) Representative IHC-stained slides of normal liver tissue.

9

10 **Figure S3.** The top 50 negative genes in HCC and CCA

11

12 **Figure S4.** GO and KEGG enrichment analysis for CCDC6. (A-B) Top 20 enrichment terms in
13 CC and MF categories in HCC. (C-D) Top 20 enrichment terms in CC and MF categories in CCA.

14

15 **Figure S5.** Correlation of CCDC6 expression with immune infiltration cells in HCC and CCA (A)
16 CCDC6 is positively correlated with the infiltration of Dendritic.Cells, Dendritic.Cells.Resting,
17 Macrophages.M0, Mast.Cells, Mast.Cells.Resting, Monocytes, NK.Cells.Resting ,
18 T.Cells.CD4.Memory.Resting and T.Cells.CD4.Naive in HCC using the TCGA database. (B)
19 CCDC6 is positively correlated with the infiltration of NK.Cells.Resting,
20 T.Cells.CD4.Memory.Resting and T.Cells.CD4.Naive in CCA using the TCGA database.




21

22 **Figure S6.** GSEA analysis (Reactomeresult and KEGG) of HCC(A,B) and CCA(C,D)


23

24 **Figure S7.** One typical HCC patient confirmed CCDC6 positive got complete response after
25 receiving targeted therapy, immunotherapy, TACE and surgery. (A). Enhanced CT-scan revealed
26 a major tumor mass before cure (white arrow). (B). Enhanced CT-scan revealed another two small
27 masses (metastasis, white arrow) before cure.(C). IHC of the tumor tissue according liver biopsy.
28 (D). Enhanced CT-scan revealed tumor regression after comprehensive therapy. (E). Enhanced
29 CT-scan revealed no reoccurrence of tumor after surgery (7 months). (i, routine scan, ii, arterial
30 phase, iii, venous phase, iv, delayed phase)


31




A HCC-negative




HCC-weak




HCC-moderate




B HCC-negative




HCC-weak




HCC-moderate




C iCCA-negative




iCCA-weak




iCCA-moderate




D Liver-negative



Liver-negative




Liver-negative




A

LIHC




B

CHOL




A

GO-CC(LIHC)




B

GO-MF(LIHC)




C



GO-CC(CHOL)




D

GO-MF(CHOL)




A**B**


A GSEA-KEGG(LIHC)




C GSEA-KEGG(CHOL)



B GSEA-Reactomeresult(LIHC)




D GSEA-Reactomeresult(CHOL)




A




B



C



D



E

